C

Cardiovascular Systems Inc
F:R7Y1

Watchlist Manager
Cardiovascular Systems Inc
F:R7Y1
Watchlist
Price: 18 EUR Market Closed
Market Cap: 759.6m EUR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

R7Y1 Price Targets Summary
Cardiovascular Systems Inc

There are no price targets for R7Y1.
R7Y1 Lowest Forecast
Wall Street Target
Not Available
R7Y1 Average Forecast
Wall Street Target
Not Available
R7Y1 Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Cardiovascular Systems Inc Competitors:
Price Targets
6849
Nihon Kohden Corp
39% Upside
J
300529
Jafron Biomedical Co Ltd
41% Upside
STE
STERIS plc
16% Upside
EKF
EKF Diagnostics Holdings PLC
28% Upside
6849
Nihon Kohden Corp
39% Upside
J
300529
Jafron Biomedical Co Ltd
41% Upside
STE
STERIS plc
16% Upside
EKF
EKF Diagnostics Holdings PLC
28% Upside
6960
Fukuda Denshi Co Ltd
1% Upside
METN
Metall Zug AG
4% Upside
STIM
Neuronetics Inc
101% Upside
NPCE
Neuropace Inc
69% Upside

Revenue
Forecast

Revenue Estimate
Cardiovascular Systems Inc

For the last 8 years the compound annual growth rate for Cardiovascular Systems Inc's revenue is 7%. The projected CAGR for the next 3 years is 12%.

7%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Cardiovascular Systems Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Cardiovascular Systems Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-25%
Average Miss
What are analyst estimates?

See Also

Summary
R7Y1 intrinsic value, competitors valuation, and company profile.
DCF Valuation
R7Y1 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
R7Y1 stock valuation using valuation multiples.
Wall Street Estimates
R7Y1 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
R7Y1 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is R7Y1's stock price target?
Not Available

R7Y1 doesn't have any price targets made by Wall Street professionals.

What is Cardiovascular Systems Inc's Revenue forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for Cardiovascular Systems Inc's revenue is 7%. The projected CAGR for the next 3 years is 12%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.